Nucleoside analogue switch

PreclinicalSmall molecule

NNorthwestern University

Nucleoside analogue switch is one of 12 small molecule programs targeting Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Atrophy

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

6 2

Namenda

AbbVie

Approved

1 3

Evrysdi

Roche

Approved

—4

Zoladex

TTerSera Therapeutics LLC

Approved

1 5

MYOBLOC

SSolstice Neurosciences

Approved

1 6

Glucophage

EMD Serono

Phase 1

1 7

Clenbuterol

UUniversity of Copenhagen

Phase 2

1 8

Estrasorb

Leuprorelin

1 10

Promestriene

UUniversity of Sao Paulo General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Completed·NNorthwestern University··NCT00225082·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nucleoside analogue switch. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nucleoside analogue switch compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nucleoside analogue switch. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthwestern University

Nucleoside analogue switch

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy1 trial

References

Drug Info

Quick Facts

Related News